List of Excipients in Branded Drug SOAANZ

SOAANZ Excipient Strategy and Commercial Opportunities

Last updated: August 4, 2026

SOAANZ is a torsemide tablet marketed by Sarfez Pharmaceuticals for edema associated with heart failure, renal disease, or hepatic disease. Its commercial differentiation depends less on the active ingredient, which is widely available as a generic, and more on dosage flexibility, formulation performance, regulatory positioning, and market access. The principal excipient opportunity is to develop a robust, low-cost immediate-release tablet that matches SOAANZ performance while improving manufacturability, dose range, swallowability, or supply economics.

What is SOAANZ and how is it positioned commercially?

SOAANZ contains torsemide, a loop diuretic administered once daily. The FDA approved SOAANZ in July 2020 under NDA 213936. The marketed product includes 20 mg, 60 mg, and 90 mg tablets, with dosing titrated according to the patient's response and clinical condition. [1]

SOAANZ competes with:

• Generic torsemide tablets, commonly available in 5 mg, 10 mg, 20 mg, and 100 mg strengths.
• Demadex, the original branded torsemide product.
• Generic furosemide and branded or generic bumetanide.
• Hospital and specialty-care diuretic protocols using intravenous loop diuretics.

The commercial thesis is based on a branded formulation and dosing strategy rather than chemical exclusivity. Torsemide has been off-patent for many years, so the product's value depends on formulation protection, regulatory exclusivity, brand prescribing, and distribution.

What excipients are used in SOAANZ tablets?

The SOAANZ prescribing information identifies the following inactive ingredients:

Excipient	Probable formulation function
Microcrystalline cellulose	Diluent and compression aid
Povidone	Binder
Crospovidone	Superdisintegrant
Sodium lauryl sulfate	Wetting agent and dissolution aid
Colloidal silicon dioxide	Glidant and flow enhancer
Magnesium stearate	Lubricant

[1]

The formulation is consistent with an immediate-release, direct-compression or highly streamlined granulation platform. The combination of microcrystalline cellulose, povidone, crospovidone, silica, and magnesium stearate supports tablet production at multiple strengths without requiring a complex modified-release system.

Sodium lauryl sulfate is strategically important. Torsemide has limited aqueous solubility relative to highly soluble salts, and a wetting agent can improve powder wetting and dissolution consistency. Its use may also reduce sensitivity to particle-size variation and hydrophobic lubrication effects.

The absence of a complex polymeric release matrix reduces manufacturing cost and simplifies scale-up. It also narrows the formulation's potential differentiation from conventional generic torsemide unless the sponsor has demonstrated clinically meaningful pharmacokinetic or dosing advantages.

How should an excipient strategy for SOAANZ be designed?

A generic or follow-on formulation should prioritize dissolution reproducibility, dose uniformity, mechanical strength, and low manufacturing complexity.

Direct-compression platform

A direct-compression formulation could use:

• Microcrystalline cellulose or silicified microcrystalline cellulose as the primary filler.
• Crospovidone or croscarmellose sodium as the disintegrant.
• Povidone or copovidone as the binder where granulation is required.
• Colloidal silicon dioxide for flow control.
• Magnesium stearate or sodium stearyl fumarate for lubrication.
• A low concentration of sodium lauryl sulfate or another wetting agent if dissolution requires enhancement.

This platform offers the lowest process burden and supports rapid manufacturing transfer. Its principal risks are segregation, content-uniformity failure at lower strengths, and sensitivity to lubricant mixing time.

Wet-granulation platform

Wet granulation may be justified if torsemide distribution is poor, powder flow is inadequate, or high-dose tablets require improved compactability. Povidone-based granulation can increase tablet strength but introduces drying and residual-moisture controls.

Wet granulation is less attractive where the commercial objective is to undercut SOAANZ on cost. It may become useful for high-throughput manufacturing if the formulation has a narrow compression window or unacceptable weight variation under direct compression.

Excipient substitution strategy

Potential substitutions should be evaluated against four criteria:

1. Dissolution profile across physiological pH conditions.
2. Content uniformity across the full strength range.
3. Tablet friability, tensile strength, and disintegration time.
4. Stability under accelerated and long-term conditions.

Possible substitution opportunities include:

SOAANZ excipient role	Alternative	Commercial rationale
Microcrystalline cellulose	Silicified MCC, mannitol, dibasic calcium phosphate	Better flow, mouthfeel, or compactability
Crospovidone	Croscarmellose sodium, sodium starch glycolate	Supply diversification and disintegration optimization
Povidone	Copovidone, pregelatinized starch	Alternative binding and granulation performance
Sodium lauryl sulfate	Poloxamer or another wetting agent	Potential tolerability or supplier diversification
Magnesium stearate	Sodium stearyl fumarate	Reduced hydrophobicity and possible dissolution benefit
Lactose-free or sugar-free filler system	Mannitol or cellulose-based system	Allergen and excipient-label differentiation

Any substitution that changes dissolution or absorption could affect bioequivalence requirements. For an ANDA, formulation flexibility exists, but the finished product must meet the applicable pharmaceutical equivalence and bioequivalence standards. For a 505(b)(2) product, a formulation change could support a new clinical or pharmacokinetic claim, but it would also increase development cost and regulatory exposure. [2]

What formulation opportunities exist beyond standard SOAANZ tablets?

The strongest commercial opportunities are dosage-form and adherence improvements rather than new chemical entities.

Lower-dose tablets

SOAANZ's marketed strengths do not cover every common torsemide starting dose. A 5 mg or 10 mg product could target:

• Early-stage heart-failure patients.
• Elderly patients requiring conservative titration.
• Patients transitioning from lower-dose generic torsemide.
• Renal patients requiring incremental dose adjustments.

A lower-strength product would compete directly with existing generic torsemide and would need a cost or usability advantage.

Scored or divisible tablets

A scored 20 mg tablet could improve titration and reduce the number of SKUs required by pharmacies. The design must demonstrate acceptable dose uniformity after splitting, particularly if the product is intended for chronic outpatient use.

Orally disintegrating tablets

An orally disintegrating torsemide tablet could target patients with dysphagia, frailty, or difficulty managing medication during acute fluid overload. The main technical challenge is taste masking. Torsemide's physicochemical properties, tablet mass, and dose strength may make an ODT more practical at low strengths than at 60 mg or 90 mg.

Potential ODT excipients include mannitol, crospovidone, co-processed excipients, silicon dioxide, and taste-masking polymers. A fast-dissolving product could support a 505(b)(2) strategy if the sponsor can establish a clinically relevant administration benefit.

Mini-tablets and multiparticulates

Mini-tablets could support flexible titration and administration through feeding tubes. Multiparticulate products could be packaged in sachets or capsules, but they would require careful control of dose uniformity, segregation, and dissolution.

Liquid formulation

A torsemide oral solution or suspension would target pediatric, geriatric, and enteral-feeding populations. Commercial feasibility depends on chemical stability, preservative selection, taste masking, and container compatibility. A liquid product could carry a stronger 505(b)(2) value proposition than another conventional tablet, but the market is narrower.

Combination products

Torsemide combinations with potassium-sparing agents or antihypertensives are technically possible but clinically complex. Electrolyte management varies substantially across heart-failure and renal populations. A fixed-dose combination would face prescribing and titration limitations that do not apply to a single-agent tablet.

What patent and regulatory protections affect SOAANZ?

SOAANZ is not protected by new-molecule exclusivity. Torsemide is an established active pharmaceutical ingredient, and generic torsemide products are approved in the United States.

The relevant protection categories are:

Protection category	Relevance to SOAANZ
New chemical entity exclusivity	Not applicable
Formulation patent	Potentially relevant if listed for the product
Method-of-use patent	Potentially relevant for dosing or patient selection claims
FDA three-year exclusivity	Potentially relevant if approval relied on new clinical investigations
Orphan-drug exclusivity	Not applicable based on the broad edema indications
Pediatric exclusivity	Requires a specific FDA pediatric-study award
Trade secret protection	Relevant to process parameters and manufacturing controls
Trademark protection	Relevant to SOAANZ branding

The Orange Book should be reviewed for current patent listings and exclusivity entries associated with NDA 213936. [3] A generic applicant should separate listed patent risk from practical formulation risk. A listed formulation patent may be challenged through Paragraph IV certification, while unlisted process know-how can still create manufacturing barriers without directly blocking ANDA approval.

When does SOAANZ lose exclusivity and when can generic entry occur?

A precise generic-entry date depends on the current Orange Book record, any patent-term adjustments, pediatric extensions, and litigation settlements. The product's active ingredient does not create a barrier because generic torsemide is already approved.

A generic applicant can pursue several pathways:

1. File an ANDA referencing SOAANZ.
2. Certify that relevant patents are invalid, unenforceable, or will not be infringed.
3. File a Paragraph IV certification if a listed patent blocks approval.
4. Launch after patent expiration, a successful litigation outcome, or an authorized settlement date.
5. Develop a non-infringing torsemide formulation with a different excipient system.

The most commercially attractive target is a high-strength tablet that matches SOAANZ's dose offerings while retaining the lower cost structure of a conventional immediate-release product.

What Paragraph IV and litigation risks exist?

Paragraph IV risk depends on the patents listed for SOAANZ, not on torsemide's historical patents. The principal litigation issues would likely involve:

• Whether the generic formulation falls within the claimed excipient ranges.
• Whether dissolution or pharmacokinetic limitations are claim elements.
• Whether a method-of-use claim covers the proposed label.
• Whether the patent is valid in view of prior torsemide formulations.
• Whether the patent claims a clinically meaningful formulation distinction.

A Paragraph IV filing could trigger a 30-month stay under the Hatch-Waxman Act if the patent holder brings suit within the statutory period. [4] A settlement could establish a negotiated generic launch date before patent expiration, but settlement terms are product-specific and should not be inferred without the filed agreement or court record.

There is no biosimilar pathway for SOAANZ. Torsemide is a small molecule, so competitive entry occurs through the ANDA pathway rather than the Biologics Price Competition and Innovation Act pathway.

How strong is the SOAANZ patent estate?

The estate is commercially moderate rather than molecule-level strong.

Its strengths are:

• A branded product with differentiated strengths.
• Potential formulation and manufacturing claims.
• Regulatory leverage if patents are properly listed.
• Ability to use brand recognition in heart failure and renal-care channels.

Its weaknesses are:

• Torsemide is an established generic molecule.
• Immediate-release tablets are technically familiar.
• Many excipient substitutions can be developed.
• Standard torsemide products already provide broad dose coverage.
• The clinical indications are broad and heavily genericized.

Patent strength would be highest if claims cover a specific dissolution or pharmacokinetic profile that is difficult to reproduce without infringing. It would be weaker if claims rely on routine excipient selection, broad concentration ranges, or conventional tablet manufacturing.

What commercial opportunities exist for excipient suppliers?

Excipient suppliers can pursue SOAANZ-related opportunities in four areas.

Supply-chain replacement

A supplier can offer dual-source or second-source materials for microcrystalline cellulose, crospovidone, povidone, silica, sodium lauryl sulfate, and magnesium stearate. The value proposition is supply continuity, not therapeutic differentiation.

Co-processed excipients

Co-processed cellulose systems could reduce blending time, improve flow, and support direct compression across multiple tablet strengths. This is relevant for manufacturers seeking a platform that can produce 20 mg, 60 mg, and 90 mg tablets without extensive process changes.

Taste and swallowability technologies

Mannitol-based fillers, coated drug particles, and taste-masking polymers could support ODTs, mini-tablets, or lower-dose products. This opportunity is more differentiated than simple excipient substitution.

Regulatory-support services

Excipient vendors can create value by supplying robust regulatory packages covering:

• United States Pharmacopeia and National Formulary compliance.
• Residual solvents and elemental impurities.
• Nitrosamine risk assessment.
• TSE/BSE status.
• Extractables and leachables.
• Microbial limits.
• Change-control history.
• Drug-master-file support.

For a low-margin generic, regulatory readiness can shorten development timelines and reduce supplier-qualification costs.

How does SOAANZ compare with other loop diuretics?

Product	Active ingredient	Typical commercial position	Excipient opportunity
SOAANZ	Torsemide	Branded oral torsemide with selected high strengths	Follow-on tablets, ODT, lower strengths
Generic torsemide	Torsemide	Low-cost standard oral therapy	Manufacturing cost and supply differentiation
Demadex	Torsemide	Legacy branded torsemide	Limited new-product leverage
Lasix and generic furosemide	Furosemide	Broadest generic use and hospital familiarity	Pediatric liquids, oral solutions, combination products
Bumex and generic bumetanide	Bumetanide	Higher-potency loop diuretic niche	Low-dose precision and parenteral-to-oral transitions

Torsemide's potential commercial advantage is once-daily oral use and high-strength dosing. Its competitive disadvantage is the availability of inexpensive generic torsemide and furosemide.

What generic launch scenarios are most likely?

The most probable entry scenarios are:

1. A conventional ANDA tablet using a similar but non-identical excipient system.
2. A high-strength generic torsemide product targeting SOAANZ's 60 mg and 90 mg strengths.
3. A lower-cost manufacturer entering with broader strengths than SOAANZ.
4. An authorized generic or licensed product launched through a commercial agreement.
5. A differentiated 505(b)(2) product using an ODT, liquid, or administration-focused formulation.

The most defensible commercial niche is a formulation that improves administration or titration. A tablet that only replaces SOAANZ's excipients without improving price, supply, dosage coverage, or patient usability is likely to compete primarily on cost.

Key Takeaways

• SOAANZ is a branded torsemide tablet approved by FDA in 2020 under NDA 213936.
• Its formulation uses conventional tablet excipients, including microcrystalline cellulose, povidone, crospovidone, sodium lauryl sulfate, colloidal silicon dioxide, and magnesium stearate.
• The strongest excipient strategy is a robust immediate-release platform optimized for dissolution, content uniformity, and direct compression.
• Commercial opportunities include lower strengths, scored tablets, orally disintegrating tablets, liquids, mini-tablets, and supply-chain replacement.
• Torsemide has no biosimilar risk because it is a small molecule.
• Generic competition is structurally strong because conventional torsemide products are already available.
• SOAANZ's patent value depends on current formulation, method-of-use, and Orange Book listings rather than active-ingredient exclusivity.
• Excipient suppliers can compete through co-processed systems, regulatory support, and improved manufacturing economics.

FAQs

Can lactose-free excipients create a meaningful SOAANZ follow-on product?

Yes. A lactose-free formulation could support patients with excipient sensitivities and simplify product positioning, but it would not by itself establish clinical differentiation. The product would still need pharmaceutical equivalence or an approved 505(b)(2) rationale.

Is sodium lauryl sulfate essential to a torsemide tablet?

Not necessarily. It may improve wetting and dissolution, but alternative surfactants or process changes could provide comparable performance. Any replacement must be evaluated for dissolution, stability, tolerability, and bioequivalence impact.

Which SOAANZ strength is most attractive for generic development?

The 60 mg and 90 mg strengths offer the clearest branded-product targeting opportunity because they are less routinely represented in standard generic torsemide portfolios. The 20 mg strength faces broader direct generic competition.

Could a torsemide oral solution receive 505(b)(2) approval?

Yes. An oral solution could use the FDA's 505(b)(2) pathway if it relies partly on an existing torsemide reference while introducing a new dosage form or administration profile. Stability, taste, dosing accuracy, preservative safety, and pharmacokinetic comparability would determine development feasibility.

Do excipient changes automatically create Paragraph IV patent risk?

No. Paragraph IV risk arises from claims in an applicable listed patent. An excipient change can avoid infringement if the claims are narrow, but it can also remain within a claim if the patent covers functional performance, concentration ranges, or broad formulation elements.

References

1. U.S. Food and Drug Administration. (2020). SOAANZ (torsemide) tablets, prescribing information. Sarfez Pharmaceuticals, Inc.

2. U.S. Food and Drug Administration. (2022). 505(b)(2) applications. Center for Drug Evaluation and Research.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. Center for Drug Evaluation and Research.

4. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98-417.